mdx2001
mAbexperimentalQuad-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 12, 2024 (NCT06239194)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Biliary Tract Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Kidney Neoplasms · Phase 1/Phase 2
- Liver Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Rectal Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Thyroid Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
CD3E activator
TACSTD2 inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
CD28 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Quad-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06239194 | Phase 1/Phase 2 (Phase 2) | Jun 12, 2024 | Opko |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Opko | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1